Amarin Corp Plc (AMRN)

[ferretmoney]

I expect "Big Data" analyses to outweigh trial data in years to come. Trial outcomes may be subject to design constraints and screening criteria biases, but real world evidence is where we are headed imo. Electronic data will show how each risk subgroup responds to each treatment variant, and cost benefit will make clear the winning treatments.

Several months ago I followed a link on some message board to a presentation by a data analytics software company that opened my eyes to what is coming. They had as a model a graphical representation of clinical outcomes to treatment/medication options.